Pharmaceutical

Menlo's Itching Drug Racks Up Two More Trial Failures, Program Ends

1 month ago   |   By Xconomy

An itching drug that was a key part of the merger of Menlo Therapeutics and Foamix Pharmaceuticals has failed two late-stage studies, leading to a halt on further development of the compound. The Menlo drug, serlopitant, was being tested in two Phase 3 clinical trials as a treatment for the itching associated with prurigo nodularis , a skin disorder that causes hard itchy lumps on the skin. The Bridgewater, NJ-based company reported Monday that patients treated with its once-daily pill showed an improvement according to a scale used to assess itching, but not enough to show that the...
Read more ...

 


Search by Tags

   Pharmaceutical      Therapeutics      Clinical      Drug      Pharmaceuticals      Drugs      National blog main      New York      New York blog main      New York top stories      San Francisco blog main      San Francisco top stories      Acne      Atopic dermatitis      Biotech      Clinical trials      David Domzalski      Foamix Pharmaceuticals      Life Sciences      Menlo Therapeutics      Merck      Minocycline      Prurigo nodularis      Pruritus      Rosacea      Serlopitant  


World Biotechnology Congress 2019

Hilaris Conferences is going to host its premier World Biotechnology Congress 2019 during October 01-02, 2019, Valencia, Spain. Biotechnology 2019 Congress aim to create a... Read more ...

World Biotechnology Congress 2019

Hilaris Conferences is going to host its premier World Biotechnology Congress 2019 during October 01-02, 2019, Valencia, Spain. Biotechnology 2019 Congress aim to create a... Read more ...

2nd International Conference on Tissue Science and Regenerative Medicine

This conference is designed for experts in academia and industries working in the tissue science and regenerative field, this conference will examine cutting-edge research in... Read more ...

Webinar: Using SMRT Sequencing to Understand SARS-CoV-2 and the Host Immune...

Webinar: Using SMRT Sequencing to Understand SARS-CoV-2 and the Host Immune Response

As the flurry of research around the SARS-CoV-2 virus continues at an unprecedented pace, scientists are beginning to tackle some of the more complex immunological responses... Read more ...

Regeneron Pays Intellia $100M to Add Hemophilia to CRISPR R&D Pact

Regeneron Pays Intellia $100M to Add Hemophilia to CRISPR R&D Pact

Four years after Regeneron Pharmaceuticals and Intellia Therapeutics began working together to research the use of CRISPR/Cas9 to treat liver diseases, the partners are... Read more ...

Marketing Coordinator - Advin Biotech - Sorrento, CA

Advin Biotech is a growing medical diagnostics company looking for a creative individual skilled in social media engagement;From Advin Biotech - Tue, 02 Jun 2020 08:54:25 GMT... Read more ...

Gene found that causes eyes to wither in cavefish

Mexican cavefish spend their entire lives in the dark. With no need for vision, many of them lost functional eyes. In more than 30 varieties of Mexican cavefish, the eyes stop... Read more ...

AnaptysBio, Inc.: Facilities Manager

AnaptysBio, Inc.: The Facilities Manager plays a key role ensuring all facilities and equipment support the Company's operations. This person oversees the daily operati San... Read more ...

Research Technician I

Position Overview San Diego Biomedical Research Institute has an opportunity immediately available for a full-time, benefits eligible Research Technician I position. The... Read more ...

Now Complete, Telescope Instrument is Poised to Begin Its Search for Answers...

This video contains animations showing how the complex components of the Dark Energy Spectroscopic Instrument, installed on the Mayall Telescope at Kitt Peak National... Read more ...

Your Brain Needs to Be Ready to Remember?

Read more ...

New Biosensor Visualizes Stress in Living Plant Cells in Real Time

Read more ...

104735 Clinical Trials Coordinator

RADIOLOGY Salary commensurate with qualifications and experienceFiling Deadline: Mon 6/15/2020... Read more ...